Navigation Links
2005 was a tough year for U.S. biotech financing

As we are still in January, it is appropriate that we continue to review biotech results for 2005 and try to find lessons learned that might help us discern trends for 2006.

Another research tool I have always found useful for this analysis is Burrill & Co.'s financial tracking information on the biotech industry. On......

Full article >>>
'"/>

Source:wistechnology.com By Michael Rosen 01/30/06


Page: 1 2 3 4 5

Related biology technology :

1. The tough choices facing health care
2. Venture-backed companies drive job creation, even in tough times
3. Vertical partnering: Street smarts for a tough marketplace
4. The state of global biotech: An Ernst & Young perspective
5. Olympics of biotechnology has international flavor
6. Getting noticed in Genetown: Wisconsin biotech on display
7. Madison biotech NimbleGen files for IPO; one of states best-funded firms
8. Wisconsin biotech firm receives $107K NIH grant
9. Manufacturing partnership will move into biotech and biomedical spaces
10. Wisconsin wont get Georgia biotech without a fight
11. The 10 biggest events shaping biotech in 2006

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: was tough year for biotech financing

(Date:11/23/2009)...origami very high-tech origami. , Researchers at...ique for fabricating three-dimensional, single-cry...pling photolithography and a self-folding process ...ly a few microns thick, offer mechanical bendabili... same material. , "This is a completely different...
(Date:11/23/2009)...arbon layer in which the carbon atoms are arranged...arbon nanotubes are rolled-up sheets of graphene, ...Graphene boasts some very special characteristics ...mal conductor, and reconciles such conflicting qua...graphene is impermeable to gases, which makes it i...
(Date:11/23/2009)...irstCall/-YMBioSciencesInc.(NYSEAmex: YMI ;TSX:YM)...iesandadvancesadiverseportfolioofpromisingcancer-r...portedthatCytopia(ASX:CYT)hascommencedenrollmentof...inisteredJAK1/JAK2inhibitor.Thetrialisbeingconduct...geCytopiaintoYMhasbeenpreviouslyannouncedandispend...
(Date:11/23/2009)...poricidin disinfectant solution and wipes are reli...ainst H1N1 and Influenza A., , ... Contec Inc, the leading manufacturer of clean ro... disinfectants have been deemed by the EPA as eff...Pandemic 2009 H1N1 influenza A virus (the swine fl...
Breaking Biology Technology:Water droplets direct self-assembly process in thin-film materials 2Polymer with honeycomb structure 2YM BIOSCIENCES REPORTS FIRST PATIENT IN PHASE I/II TRIAL OF JAK1/JAK2 INHIBITOR, CYT387 ENROLLED BY CYTOPIA 2YM BIOSCIENCES REPORTS FIRST PATIENT IN PHASE I/II TRIAL OF JAK1/JAK2 INHIBITOR, CYT387 ENROLLED BY CYTOPIA 3YM BIOSCIENCES REPORTS FIRST PATIENT IN PHASE I/II TRIAL OF JAK1/JAK2 INHIBITOR, CYT387 ENROLLED BY CYTOPIA 4Sporicidin Brand Disinfectant Kills H1N1 in 3 Minutes 2
..., Mass., March 31 Tryton Medical, Inc., the,leadi... treatment of,bifurcation lesions announced today ... financing. Two new investors, PTV Sciences and Ri... Partners in the financing. Rick Anderson,from PTV...ted to the Tryton,Board of Directors., "Bifurcati...
...eneration Pyrosequencing(R) System; PyroMark(TM)Q2...or Low Throughput Epigenetic Studies, UPPSALA, Sw... Biotage AB today announced the launch of PyroMark...R) Systems. This new high-performance,platform inc... genetic and,epigenetic variation of genes, provid...
...Quarter 2008 Earnings Conference Call Thursday, Ma....S. EDT, FRAZER, Pa., March 31 Cephalon, Inc.,(...y earnings conference call,covering first quarter ...2008., May 1, 2008 Sched...tributed by PRNewswire 4:50 p.m. EDT To partic...
Other Biology Technology:Tryton Medical, Inc. Closes $14 Million Financing 2Tryton Medical, Inc. Closes $14 Million Financing 3Biotage Launches New 24 Well Pyrosequencing(R) System 2
(Date:11/22/2009)...xposed prenatally to tobacco smoke and during chil...HD, according to research done at Cincinnati Child...ates that up to 35 percent of ADHD cases in childr...y eliminating both of these environmental exposure...n , "Tobacco and lead exposure each have their ...
(Date:11/22/2009)...r 23, 2009 Agios Pharmaceuticals today announced ...t time, that the mutated IDH1 gene has a novel enz..., or oncogene. This breakthrough discovery shows t..., 2-hydroxyglutarate (2HG), which may contribute t...as, the most common type of brain cancers. This di...
(Date:11/20/2009)... all read studies about the health benefits of hav...molecular level, where amino acids known as cystei... than when paired up with other cysteines. , Now... with colleagues in Belgium, have discovered a new.... The research appears in the Nov. 20 issue of the...
Breaking Biology News(10 mins):Exposure to lead, tobacco smoke raises risk of ADHD 2Cancer metabolism discovery uncovers new role of IDH1 gene mutation in brain cancer 2Cancer metabolism discovery uncovers new role of IDH1 gene mutation in brain cancer 3Cancer metabolism discovery uncovers new role of IDH1 gene mutation in brain cancer 4Saving the single cysteine: New antioxidant system found 2Maui Jim Teams With Unite for Sight in New Buy One Give One Program to Improve Eye Health Amongst the Worlds Most Needy 49888 1Maui Jim Teams With Unite for Sight in New Buy One Give One Program to Improve Eye Health Amongst the Worlds Most Needy 49888 2Maui Jim Teams With Unite for Sight in New Buy One Give One Program to Improve Eye Health Amongst the Worlds Most Needy 49888 3The Crohns 26 Colitis Foundation and Procter 26 Gamble Pharmaceuticals Announce 2009 Celebrating UC Success Contest Winners 49883 1The Crohns 26 Colitis Foundation and Procter 26 Gamble Pharmaceuticals Announce 2009 Celebrating UC Success Contest Winners 49883 2The Crohns 26 Colitis Foundation and Procter 26 Gamble Pharmaceuticals Announce 2009 Celebrating UC Success Contest Winners 49883 3The Crohns 26 Colitis Foundation and Procter 26 Gamble Pharmaceuticals Announce 2009 Celebrating UC Success Contest Winners 49883 4The Crohns 26 Colitis Foundation and Procter 26 Gamble Pharmaceuticals Announce 2009 Celebrating UC Success Contest Winners 49883 5Availability in Both Intravenous and Oral Formulation is a Leading Drug Attribute Surveyed Physicians Prefer for the Treatment of Urinary Tract Infect 49878 1Availability in Both Intravenous and Oral Formulation is a Leading Drug Attribute Surveyed Physicians Prefer for the Treatment of Urinary Tract Infect 49878 2Availability in Both Intravenous and Oral Formulation is a Leading Drug Attribute Surveyed Physicians Prefer for the Treatment of Urinary Tract Infect 49878 3
...tudy in 50 people in Japan suggests that eating tw...two months may confer some protection against a ra...d even stomach cancer. , Citing their new "demon...archer and an international team of scientists cau...id not cure infection by the bacterium Helicobact...
...ril 3 The General Services Administration (GSA) h...CH) as a provider of Personal Identity Verificatio...ation managed services, under Homeland Security Pr...fication, ABBTECH will offer services through thei...2 as an approved service provider. Services prov...
...chers from the Massachusetts General Hospital Cent... the first evidence of cell-to-cell communication ...ather than by known protein signaling agents such ... appear in an upcoming issue of the FASEB Journal... by complete surprise," says Rohit Jindal, PhD, a ...
Other Biology News:Gutsy germs succumb to baby broccoli 2Gutsy germs succumb to baby broccoli 3Gutsy germs succumb to baby broccoli 4ABBTECH Staffing Services Certified by GSA as an HSPD-12 Managed Service Provider 2Model tissue system reveals cellular communication via amino acids 2
Mouse Anti-GLP-1 Monoclonal Antibody, Unconjugated, Clone HYB 147-12 from Santa Cruz Biotechnology, Inc.
Baculovirus system service from Abgent
21-mer duplex design + syn.; 1 gene from B-Bridge International
EDTA, tetrasodium salt from GE Healthcare, formerly Amersham Biosciences
Biology Products: